[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


2. Taguchi I, Minayoshi K, Ito N, Kameyama H, Adachi Y, Miyake T: [Malignant lymphoma of the prostate: a case report]. Hinyokika Kiyo; 2001 May;47(5):337-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the prostate: a case report].
  • A case of a primary malignant lymphoma of the prostate is presented.
  • An 82-year-old man visited our hospital complaining of anal pain.
  • According to the Working Formulation, he was diagnosed with non-Hodgkin's lymphoma of B-cell origin, diffuse, mixed, small and large cell.
  • The results of bone marrow puncture and imaging studies led to the diagnosis of primary malignant lymphoma of the prostate.
  • Because of poor performance status deriving from severe anal pain, radiation therapy was performed to control the pain.
  • After improvement of his performance status, he received combination chemotherapy consisting of cyclophosphamide, adriamycin, vincristine and predonisone (CHOP regimen).
  • His prostate markedly diminished in size, but pneumonia developed.
  • Malignant lymphoma involving the prostate, whether primary or secondary, is very rare.
  • In our understanding, this case is thought to be the 28th clinical case of a malignant lymphoma of the prostate in Japan.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11433756.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


3. Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI: Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res; 2010 Oct 1;16(19):4755-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata.
  • EXPERIMENTAL DESIGN: We studied the Burkitt p53-mutated Ramos cell line, the mantle cell lymphoma (MCL) line Granta, the follicular lymphoma (FL) cell line HF-1, and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4, as well as primary cells from patients with FL, DLBCL, and MCL.
  • RESULTS: We found that andrographolide resulted in dose- and time-dependent cell death as measured by MTT.
  • CONCLUSIONS: Andrographolide caused ROS-dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK.
  • Further studies of diterpenoid lactones in lymphoma are warranted.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Phytomedicine. 2000 Oct;7(5):351-64 [11081986.001]
  • [Cites] J Exp Ther Oncol. 2003 May-Jun;3(3):147-58 [14641821.001]
  • [Cites] J Clin Pharm Ther. 2004 Feb;29(1):37-45 [14748896.001]
  • [Cites] J Ethnopharmacol. 2004 Jun;92(2-3):291-5 [15138014.001]
  • [Cites] BMC Cancer. 2004 Jun 18;4:26 [15207007.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Sep 20;14(18):4711-7 [15324893.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):4207-17 [15356172.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1999 Feb 15;338 ( Pt 1):107-13 [9931305.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jan;312(1):366-72 [15331658.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1265-73 [15388578.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Br J Pharmacol. 2005 Mar;144(5):680-6 [15678086.001]
  • [Cites] In Vivo. 2005 May-Jun;19(3):551-7 [15875775.001]
  • [Cites] Planta Med. 2005 Dec;71(12):1106-11 [16395645.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Biochem Pharmacol. 2006 Jul 14;72(2):132-44 [16740251.001]
  • [Cites] Pak J Pharm Sci. 2007 Jan;20(1):9-15 [17337421.001]
  • [Cites] Methods. 2008 Mar;44(3):229-34 [18314053.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Apr;325(1):226-35 [18174384.001]
  • [Cites] J Asian Nat Prod Res. 2008 May-Jun;10(5-6):467-73 [18464090.001]
  • [Cites] J Nat Prod. 2008 May;71(5):852-5 [18357994.001]
  • [Cites] J Cell Sci. 2008 Jul 1;121(Pt 13):2186-96 [18544634.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2170-80 [18645026.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2008 Dec;6(12):1238-45 [19063836.001]
  • [Cites] J Pharm Pharmacol. 2009 Jan;61(1):69-78 [19126299.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):502-6 [19158000.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R104 [19061505.001]
  • [Cites] Cancer Lett. 2009 Apr 18;276(2):180-8 [19097688.001]
  • [Cites] Drug Metab Lett. 2008 Dec;2(4):261-8 [19356103.001]
  • [Cites] Oncogene. 2009 Jul 23;28(29):2690-6 [19503098.001]
  • [Cites] Int J Toxicol. 2009 Jul-Aug;28(4):308-17 [19636073.001]
  • [Cites] Redox Rep. 2009;14(4):176-84 [19695125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1232-9 [20610044.001]
  • [Cites] Phytother Res. 2000 Aug;14(5):333-8 [10925397.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • (PMID = 20798229.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Reactive Oxygen Species; 410105JHGR / andrographolide
  • [Other-IDs] NLM/ NIHMS231241; NLM/ PMC2948634
  •  go-up   go-down


Advertisement
4. Gates AE, Kaplan LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park); 2002 May;16(5):657-65; discussion 665, 668-70
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies in the era of highly active antiretroviral therapy.
  • The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with human immunodeficiency virus (HIV).
  • The incidence of Kaposi's sarcoma (KS) and primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART in 1995.
  • Systemic non-Hodgkin's lymphoma (NHL) appears to be declining in incidence as well, but to a lesser degree than KS and PCNSL.
  • The impact of HAART on the epidemiology of other HIV-associated malignancies, including Hodgkin's disease and anal carcinoma, remains unclear.
  • Data regarding the impact of HAART on the natural history and treatment outcomes of HIV-associated malignancies are limited.
  • The possibility of direct and indirect roles of HIV in HIV-related carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment strategy for several HIV-related malignancies.
  • Patients with HIV-NHL treated with HAART in addition to chemotherapy experience fewer intercurrent opportunistic infections.
  • Furthermore, the simultaneous administration of HAART and chemotherapy does not appear to significantly increase toxicity.
  • Whether the combination of HAART and standard therapy results in improved survival remains uncertain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Central Nervous System Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Female. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Male


5. Ganser A, Roth G, van Galen JC, Hilderink J, Wammes JJ, Müller I, van Leeuwen FN, Wiesmüller KH, Brock R: Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy. Anal Chem; 2009 Jul 1;81(13):5233-40
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy.
  • Combination therapies have proven vital in the fight against HIV and cancer.
  • However, the identification and optimization of such combination therapies is largely experience driven and an activity of clinicians rather than of systematic screening efforts.
  • Applications to the testing of different drug combinations and the parallel screening of different leukemia cell lines as well as primary patient cells are presented.
  • Given its ease of handling, the device will greatly advance the development and optimization of combination drugs and the identification of optimum drug combinations in personalized medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Toxicity Tests / instrumentation
  • [MeSH-minor] Adenine Nucleotides / pharmacology. Annexin A5 / chemistry. Annexin A5 / pharmacology. Arabinonucleosides / pharmacology. Cell Death / drug effects. Diffusion. Dose-Response Relationship, Drug. Doxorubicin / pharmacology. Drug Therapy, Combination. Fluorescent Dyes / chemistry. Humans. Miniaturization. Phosphatidylserines / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476343.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Annexin A5; 0 / Arabinonucleosides; 0 / Fluorescent Dyes; 0 / Phosphatidylserines; 762RDY0Y2H / clofarabine; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • METHODS AND RESULTS: A 38-year-old HIV+ Rwandan farmer had an 8-cm x 13-cm anal tumor.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • Chemotherapy in combination of virostatic therapy is the gold standard for treatment, but because of economic constraints surgical treatment was the only practicable intervention and an abdominoperineal resection of the anorectum was performed.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • Adequate treatment is available for only a small percentage of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Place RJ, Huber PJ, Simmang CL: Anorectal lymphoma and AIDS: an outcome analysis. J Surg Oncol; 2000 Jan;73(1):1-4; discussion 4-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal lymphoma and AIDS: an outcome analysis.
  • BACKGROUND AND OBJECTIVE: Primary lymphoma of the anus is an extremely rare problem.
  • METHODS: Over an 18-year period, we identified 6 patients with AIDS and primary anorectal NHL.
  • No benefit was shown from radiation or chemotherapy in those with "B" symptoms.
  • Younger patients and those without systemic constitutional symptoms of lymphoma do better.
  • One patient without "B" symptoms was able to tolerate his radiation and chemotherapy and is disease free at 10 months.
  • CONCLUSION: Despite traditional non-Hodgkin's lymphoma treatment regimens, our AIDS patients (and those examined in a review of the pertinent literature) with anorectal NHL and "B" symptoms have a poor prognosis.
  • For those without "B" symptoms and who can tolerate the therapy, NHL remission may be obtained.
  • [MeSH-major] Anus Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10649269.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


8. Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, Nikolovska-Coleska Z, Lin Y, Ling X, Yang D, Wang S, Al-Katib A, Mohammad RM: Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther; 2008 Sep;7(9):1418-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
  • The principal objective of this study was to compare stability and toxicity between ApoG2 and gossypol, and to evaluate anti-lymphoma activity of ApoG2 in vitro and in vivo.
  • ApoG2 showed significant inhibition of cell proliferation of WSU-DLCL(2) and primary cells obtained from lymphoma patients, whereas it displayed no toxicity on normal peripheral blood lymphocytes.
  • For a treatment of 72 h, the IC(50) of ApoG2 was determined to be 350 nM against WSU-DLCL2 cells.
  • Treatment with ApoG2 at 600 mg/kg resulted in significant growth inhibition of WSU-DLCL(2) xenografts.
  • For a treatment of 72 h, ApoG2 induced a maximum of 32% of apoptotic cell death.
  • Western blot experiments showed that treatment with ApoG2 led to cleavage of caspase-3, caspase-9 and PARP.
  • It is an attractive small molecule inhibitor of the Bcl-2 family proteins to be developed further for the treatment of diffuse large cell lymphoma.

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2226-35 [17404107.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Mar;7(3):257-73 [17338647.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):559-65 [17499214.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5430-8 [17332241.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2236-40 [17881896.001]
  • [Cites] Clin Transl Oncol. 2007 Sep;9(9):555-62 [17921102.001]
  • [Cites] Drug Resist Updat. 2007 Dec;10(6):207-17 [17921043.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2008 Jan;3(1):20-30 [18289121.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):63-73 [17356822.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1498-502 [10749111.001]
  • [Cites] Anticancer Drugs. 2000 Mar;11(3):209-16 [10831280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4950-6 [11156256.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Apr 9;11(7):887-90 [11294384.001]
  • [Cites] J Med Chem. 2001 Dec 6;44(25):4313-24 [11728179.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):679-83 [11895895.001]
  • [Cites] Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10 [12710585.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):313-7 [12720160.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1391-4 [15359638.001]
  • [Cites] Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 [4202581.001]
  • [Cites] Cancer. 1978 Oct;42(4):1705-10 [361209.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7 [8221615.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]
  • [Cites] Curr Opin Oncol. 1995 Nov;7(6):541-6 [8547403.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] Contraception. 1995 Dec;52(6):389-95 [8749604.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27886-92 [9346936.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2134-40 [9605757.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1305-14 [9607591.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):324-30 [9704409.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Curr Opin Chem Biol. 1999 Aug;3(4):500-9 [10419854.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jul;56(1):46-54 [15791457.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Apoptosis. 2006 Apr;11(4):459-71 [16547596.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] J Mol Biol. 2006 Dec 1;364(3):536-49 [17011577.001]
  • [Cites] Front Biosci. 2007;12:4722-30 [17485408.001]
  • (PMID = 18769131.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / R01 CA109389; United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Recombinant Proteins; 0 / apogossypol; 0 / bcl-X Protein; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS521870; NLM/ PMC4106024
  •  go-up   go-down


9. Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, Tsianos EV: Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand J Gastroenterol; 2006 Jul;41(7):866-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature.
  • Seven years after the adenocarcinoma diagnosis, the patient presented with severe continuous anal pain and diarrhea.
  • In parallel with antibiotic administration, the patient was given treatment with Infliximab, but without clinical symptom amelioration.
  • Sigmoidoscopy and subsequent biopsies from an ulcerated rectal area supported the diagnosis of Epstein-Barr virus-positive (EBV+) primary Hodgkin's lymphoma.
  • Infliximab administration was immediately discontinued and the patient underwent oncological follow-up and began a course of chemotherapy.
  • Only a few cases with primary gastrointestinal Hodgkin's lymphoma in Crohn's disease patients have so far been reported, including a variety of scenarios on the causal relationship including disease duration, presence of EBV, long-term immunosuppressive treatment and, recently, anti-TNFalpha administration.
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / virology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785203.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 28
  •  go-up   go-down


10. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP: Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol; 2009 Oct;72(1):10-20
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
  • Despite the impact of combined antiretroviral therapy (cART) on human immunodeficiency virus (HIV)-related mortality, malignancies remain the second most common cause of death in HIV infection in developed countries.
  • In addition to the AIDS-defining malignancies, other cancers such as Hodgkin's lymphoma and anal cancer, are more frequent in HIV-infected patients who survive longer even though they do not have complete immune restoration The use of concomitant antineoplastic chemotherapy and cART have been demonstrated to be feasible and effective in patients with HIV-related malignancies; however, many drugs used in cART regimens have the potential for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.
  • Since many antineoplastic drugs are also metabolised by the CYP system, co-administration with cART could result in either drug accumulation and possible toxicity, or rapid drug metabolism and decreased efficacy.
  • Unfortunately, very limited prospective interaction data are available to safely guide the combined use of cART and chemotherapy.
  • This paper reviews the potential drug interactions and therapeutic considerations of the antiretroviral agents used to treat HIV and the most common anticancer agents used in the treatment of malignancies found in patients with HIV infection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Neoplasms / drug therapy. Neoplasms / etiology
  • [MeSH-minor] Drug Interactions. Drug Therapy, Combination. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070506.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


11. Gates AE, Kaplan LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park); 2002 Apr;16(4):441-51, 456, 459
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies in the era of highly active antiretroviral therapy.
  • The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with human immunodeficiency virus (HIV).
  • The incidence of Kaposi's sarcoma (KS) and primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART in 1995.
  • Systemic non-Hodgkin's lymphoma (NHL) appears to be declining in incidence as well, but to a lesser degree than KS and PCNSL.
  • The impact of HAART on the epidemiology of other HIV-associated malignancies, including Hodgkin's disease and anal carcinoma, remains unclear.
  • Data regarding the impact of HAART on the natural history and treatment outcomes of HIV-associated malignancies are limited.
  • The possibility of direct and indirect roles of HIV in HIV-related carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment strategy for several HIV-related malignancies.
  • Patients with HIV-NHL treated with HAART in addition to chemotherapy experience fewer intercurrent opportunistic infections.
  • Furthermore, the simultaneous administration of HAART and chemotherapy does not appear to significantly increase toxicity.
  • Whether the combination of HAART and standard therapy results in improved survival remains uncertain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active / adverse effects. Central Nervous System Neoplasms / etiology. Lymphoma, Non-Hodgkin / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] Anus Neoplasms / epidemiology. Anus Neoplasms / etiology. Humans. Immunocompromised Host. Incidence. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / etiology. Risk Factors


12. Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U: Therapeutic approaches to AIDS-related malignancies. Oncogene; 2003 Sep 29;22(42):6646-59
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approaches to AIDS-related malignancies.
  • The introduction of highly active antiretroviral therapy (HAART) has changed dramatically the landscape of HIV disease.
  • Deaths from AIDS-related diseases have been reduced by 75% since protease inhibitor therapy and combination antiretroviral therapy came into use in late 1995.
  • While KS is declining, the situation for non-Hodgkin's lymphoma is more complex with a reduced incidence of primary central nervous system lymphoma, but a relatively stability in the number of patients developing systemic NHL.
  • AIDS related NHL appears not to be markedly decreased by the introduction of HAART and it is the greatest therapeutic challenge in the area of AIDS oncology.
  • Furthermore, also for the prolongation of the survival expectancy of these patients, other non AIDS-defining tumors, such as Hodgkin's disease, anal and head and neck, lung and testicular cancer, and melanoma have been recently reported with increased frequency in patients with HIV infection.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / therapy
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. HIV Infections / complications. HIV Infections / drug therapy. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / prevention & control

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14528290.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 124
  •  go-up   go-down


13. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, Costagliola D, Salmon D, Chêne G, Morlat P: Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer; 2004 Jul 15;101(2):317-24
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
  • BACKGROUND: Before the introduction of highly active antiretroviral therapy (HAART), malignancies accounted for less than 10% of all deaths among human immunodeficiency virus (HIV)-infected patients.
  • This figure may have increased, and the observed types of malignant disease may have been modified, as a result of decreased occurrence of opportunistic infections, the chronicity of HIV infection, the possible oncogenic role of HIV itself, and the aging of the HIV-infected population.
  • Acquired immunodeficiency virus (AIDS)-related malignancies were the underlying cause of 149 deaths (15%); among these malignancies were non-Hodgkin lymphoma (n = 105 [11%]), noncerebral lymphoma (n = 78 [median CD4 count, 86 x 10(6) per liter; interquartile range [IQR], 35-231 x 10(6) per liter), and primary cerebral lymphoma (n = 27 [median CD4 count, 20 x 10(6) per liter; IQR, 4-109 x 10(6) per liter).
  • Non-AIDS-related malignancies were the underlying cause of 120 deaths (13%); these non-AIDS-related malignancies included 103 solid tumors (50 respiratory tumors, 19 hepatocarcinomas, 9 digestive tumors, and 6 anal tumors; median CD4 count, 218 x 10(6) per liter; IQR, 108-380 x 10(6) per liter) and 17 hemopathies (12 Hodgkin lymphomas, 4 myeloid leukemias, and 1 myeloma; median CD4 count, 113 x 10(6) per liter; IQR, 56-286 x 10(6) per liter).
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Neoplasms / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / mortality. Adult. Female. France / epidemiology. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Prospective Studies


14. Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G: The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood; 2009 Mar 19;113(12):2776-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.
  • Anaplastic large cell lymphoma represents a subset of neoplasms caused by translocations that juxtapose the anaplastic lymphoma kinase (ALK) to dimerization partners.
  • ATIC phosphorylation was documented in cell lines and primary tumors carrying ALK proteins and other tyrosine kinases, including TPR-Met and wild type c-Met.
  • Prediction of tumor responses to methotrexate may justify specific molecular-based chemotherapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Nov 16;38(46):15388-97 [10563825.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1097-104 [16464493.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):781-9 [10702393.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Life Sci. 2000;66(23):2297-307 [10855951.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2000 Aug;56(Pt 8):1051-4 [10944351.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7727-33 [11096114.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Clin Chem. 2002 Jun;48(6 Pt 1):835-43 [12028998.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5823-34 [12185581.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):137-46 [12716127.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5 [3860829.001]
  • [Cites] Blood. 1989 May 1;73(6):1468-75 [2469492.001]
  • [Cites] J Mol Biol. 1992 Sep 5;227(1):283-92 [1522592.001]
  • [Cites] J Biol Chem. 1996 Jan 26;271(4):2225-33 [8567683.001]
  • [Cites] Adv Exp Med Biol. 1998;431:221-6 [9598063.001]
  • [Cites] J Biol Chem. 1957 Sep;228(1):201-13 [13475309.001]
  • [Cites] Anal Biochem. 1963 Jul;6:100-8 [13995604.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47726-31 [15358777.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] Mol Cell Proteomics. 2005 Mar;4(3):310-27 [15665377.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1787-98 [16785248.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4202-4 [16946300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):740-7 [17110082.001]
  • [Cites] Mol Cancer. 2007;6:25 [17407558.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7 [18180459.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3907-16 [16105984.001]
  • [Cites] Biochem J. 2006 Jan 15;393(Pt 2):555-64 [16197368.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7402-7 [16651537.001]
  • [Cites] Proteomics. 2006 May;6(10):3210-22 [16596703.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4888-97 [16497976.001]
  • [CommentIn] Blood. 2009 Mar 19;113(12):2615-6 [19299651.001]
  • (PMID = 18845790.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090773; United States / NCI NIH HHS / CA / R01-CA90773
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CEP 11988; 0 / CEP 14083; 0 / Carbazoles; 0 / Cell Adhesion Molecules; 0 / Indazoles; 0 / Microfilament Proteins; 0 / Multienzyme Complexes; 0 / Neoplasm Proteins; 0 / Phenylurea Compounds; 0 / Phosphoproteins; 0 / Protein Kinase Inhibitors; 0 / inosine monophosphate synthase; 0 / vasodilator-stimulated phosphoprotein; 21820-51-9 / Phosphotyrosine; EC 2.1.2.- / Hydroxymethyl and Formyl Transferases; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.4.- / Nucleotide Deaminases; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2661863
  •  go-up   go-down


15. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood; 2008 Sep 1;112(5):1912-22
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, and resistance to fludarabine-based therapies is a major challenge in CLL treatment.
  • Using primary CLL cells and normal lymphocytes from patients (n = 58) and healthy subjects (n = 12), we showed that both fludarabine-resistant and -sensitive CLL cells were highly sensitive to beta-phenylethyl isothiocyanate (PEITC) with mean IC(50) values of 5.4 microM and 5.1 microM, respectively.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jun 17;23(28):4818-27 [15122313.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]
  • [Cites] Am J Hematol. 2004 Jan;75(1):22-33 [14695629.001]
  • [Cites] Drug Resist Updat. 2003 Dec;6(6):323-8 [14744496.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Mar;53(3):209-19 [14610616.001]
  • [Cites] Arch Biochem Biophys. 2004 Mar 1;423(1):37-46 [14989263.001]
  • [Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):499-512 [17707836.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8653-61 [17875705.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):32233-42 [17823113.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Br J Haematol. 1989 May;72(1):32-5 [2786733.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Blood. 1993 Jan 1;81(1):143-50 [8093345.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 17;206(2):748-55 [7826396.001]
  • [Cites] Jpn J Pharmacol. 1996 Aug;71(4):299-305 [8886927.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Semin Liver Dis. 1998;18(4):389-401 [9875556.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 1;37(11):1821-33 [15528041.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1934-40 [15483672.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):640-5 [15577914.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4738-44 [15550399.001]
  • [Cites] Biochemistry. 2005 Apr 19;44(15):5899-906 [15823049.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4820-7 [15728130.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):123-7 [16001073.001]
  • [Cites] Free Radic Res. 2005 Jun;39(6):573-80 [16036334.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3482-92 [16163384.001]
  • [Cites] Braz J Med Biol Res. 2006 Mar;39(3):327-33 [16501812.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):437-45 [16272172.001]
  • [Cites] Crit Rev Clin Lab Sci. 2006;43(2):143-81 [16517421.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):210-9 [16616068.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Expert Opin Pharmacother. 2006 Aug;7(12):1641-51 [16872267.001]
  • [Cites] Cancer Cell. 2006 Sep;10(3):241-52 [16959615.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):311-20 [17325891.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Biochemistry. 2007 Jul 3;46(26):7765-80 [17555331.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6409-16 [17616701.001]
  • [Cites] Clin Chim Acta. 2000 Mar;293(1-2):53-62 [10699422.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1405-13 [10942236.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):183-93 [10998361.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Anal Biochem. 2001 Apr 15;291(2):279-89 [11401302.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1795-801 [12176902.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43730-4 [12223490.001]
  • [Cites] Blood. 2003 May 15;101(10):4098-104 [12531810.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37832-9 [12853461.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S73-85 [15105835.001]
  • (PMID = 18574029.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100428; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA085563; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA109041; United States / NCI NIH HHS / CA / R01 CA109041; United States / NCI NIH HHS / CA / CA100428; United States / NCI NIH HHS / CA / CA085563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isothiocyanates; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 6U7TFK75KV / phenethyl isothiocyanate; 9007-43-6 / Cytochromes c; EC 1.11.1.9 / Glutathione Peroxidase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; FA2DM6879K / Vidarabine; GAN16C9B8O / Glutathione; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2518893
  •  go-up   go-down


16. Grulich AE: Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy. AIDS Read; 2000 Jun;10(6):341-6
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy.
  • The incidence of AIDS-defining opportunistic infections has decreased markedly in persons with HIV who receive combination antiretroviral therapy, but less is known regarding the incidence of cancer.
  • It does appear that the incidence of Kaposi sarcoma in persons receiving combination therapy has fallen dramatically.
  • In contrast, reduction in the incidence of non-Hodgkin lymphoma (NHL) has been smaller.
  • Based on few data, it appears that the incidence of primary CNS NHL is significantly decreasing, whereas the incidence of systemic NHL has changed little.
  • Certain other cancers, comprising cervical cancer, Hodgkin disease, anal cancer, and conjunctival cancer, occur at increased rates in some populations with AIDS, but there are few data on incidence trends since the widespread use of combination therapy.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. Neoplasms / epidemiology
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Drug Therapy, Combination. Female. Humans. Male. Risk Factors


17. Silverberg MJ, Abrams DI: Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS; 2009 Jan;4(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the antiretroviral therapy (ART) era.
  • NADMs associated with immunosuppression included Hodgkin's lymphoma, oral/pharynx, lung, anal, and colorectal cancers.
  • Despite the potential protective effect of ART on some NADMs, recent studies evaluating calendar era trends have noted an increased risk of Hodgkin's lymphoma and anal cancer and no change in risk for lung cancer in the ART era.
  • However, a continued high risk in the ART era for certain cancers have been observed, including Hodgkin's lymphoma and anal cancers.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):304-12 [17570119.001]
  • [Cites] AIDS. 1997 Aug;11(10):1300-1 [9256954.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] AIDS. 1997 Nov;11(13):1653-5 [9365774.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):271-8 [17460771.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5183-94 [17785575.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10920-8 [18006837.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Feb;24(2):163-8 [18240964.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Addiction. 2008 Apr;103(4):651-9 [18339110.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90 [18614916.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):339-54 [18650512.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1251-8 [18618279.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1809-15 [10673996.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] Blood. 2002 May 15;99(10):3771-9 [11986235.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):384-90 [12447008.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):537-47 [12965274.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7426-31 [15492266.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] AIDS. 1997 Feb;11(2):261-2 [9030382.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • (PMID = 19339938.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI068641; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI068641; United States / NIAID NIH HHS / AI / U01 AI068641-03; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / UM1 AI068641; United States / NIAID NIH HHS / AI / AI071725-02; United States / NIAID NIH HHS / AI / AI068641-03; United States / NIAID NIH HHS / AI / K01 AI071725-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS94539; NLM/ PMC2698664
  •  go-up   go-down


18. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Antiretroviral agents have a propensity for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.
  • Because many antineoplastic drugs are also metabolized by the CYP system, coadministration with cART could result in either drug accumulation with increased toxicity, or decreased efficacy of one or both classes of drugs.
  • Further research delineating the combined safety and pharmacokinetics of antiretrovirals and antineoplastic therapy is necessary.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Neoplasms / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


19. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK: Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest; 2008 May;118(5):1750-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knockout and transgenic studies in mice demonstrate that normal somatic tissues redundantly express 3 cyclin D proteins, whereas tumor cells seem dependent on a single overexpressed cyclin D.
  • Thus, selective suppression of the individual cyclin D deregulated in a tumor represents a biologically valid approach to targeted cancer therapy.
  • Kinetin riboside induced marked suppression of CCND2 transcription and rapidly suppressed cyclin D1 and D2 protein expression in primary myeloma cells and tumor lines, causing cell-cycle arrest, tumor cell-selective apoptosis, and inhibition of myeloma growth in xenografted mice.
  • These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. KINETIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 9;279(1):69-73 [11112419.001]
  • [Cites] J Endocrinol. 2006 Mar;188(3):623-33 [16522741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10487-92 [11504909.001]
  • [Cites] Cell Growth Differ. 2002 Jan;13(1):19-26 [11801528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6 [11904383.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20724-33 [11923289.001]
  • [Cites] Genes Dev. 2002 Dec 15;16(24):3277-89 [12502747.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):415-21 [12504100.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1729-35 [12685824.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3317-22 [12829606.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3501-8 [15116089.001]
  • [Cites] Nature. 2004 Jun 3;429(6991):566-71 [15152264.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] PLoS Biol. 2004 Sep;2(9):E311 [15367944.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2170-80 [16301994.001]
  • [Cites] J Gene Med. 2006 Apr;8(4):442-51 [16389604.001]
  • [Cites] Nat Immunol. 2006 May;7(5):489-97 [16582912.001]
  • [Cites] Biol Reprod. 2006 Aug;75(2):279-88 [16625003.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):715-9 [16929317.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3232-9 [17148759.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):131-44 [17692805.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3517-25 [17673602.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4047-54 [17875808.001]
  • [Cites] Int J Biol Macromol. 2004 Aug;34(4):271-5 [15374684.001]
  • [Cites] Mutat Res. 1979 Feb;66(2):103-12 [372796.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1179-91 [8458330.001]
  • [Cites] Dermatol Clin. 2000 Oct;18(4):609-15 [11059368.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):314-20 [8397338.001]
  • [Cites] Cell. 1993 Dec 3;75(5):875-86 [8252624.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1295-304 [8134134.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1720-8 [8137287.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):9090-9 [8621559.001]
  • [Cites] Anal Biochem. 1996 May 1;236(2):221-8 [8660498.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):470-4 [8945475.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10859-69 [9099742.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4029-35 [9307289.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):637-46 [9531328.001]
  • [Cites] EMBO J. 1998 Oct 1;17(19):5734-43 [9755173.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):3015-9 [9881703.001]
  • [Cites] Science. 1999 Mar 5;283(5407):1541-4 [10066178.001]
  • [Cites] Skinmed. 2004 Nov-Dec;3(6):339 [15538084.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D459-65 [15608237.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(3):1081-8 [15657434.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1032-42 [15592507.001]
  • [Cites] Cell Cycle. 2005 Mar;4(3):388-91 [15738651.001]
  • [Cites] Exp Hematol. 2005 Jun;33(6):652-9 [15911089.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8012-7 [16258099.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 27;829(1-2):26-34 [16216563.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D556-61 [16381931.001]
  • [Cites] Facial Plast Surg Clin North Am. 2001 May;9(2):189-96, vii [11457685.001]
  • (PMID = 18431519.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA100707-070008; United States / NCI NIH HHS / CA / CA100707-070008; United States / NIA NIH HHS / AG / R01 AG020686; United States / NIA NIH HHS / AG / R01 AG020686-05; United States / NCI NIH HHS / CA / P50 CA100707
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / Nucleosides; P39Y9652YJ / Kinetin
  • [Other-IDs] NLM/ PMC2323188
  •  go-up   go-down


20. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
Hazardous Substances Data Bank. L-Ascorbic Acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary end point was objective response.
  • In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl-2 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment.
  • The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17).
  • Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%.
  • Intracellular depletion of glutathione was not consistently observed during treatment.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


21. Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM: A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol; 2008 Nov;90(2):229-35
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
  • Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM).
  • The primary endpoint was tumor response, assessed by MRI.
  • RESULTS: Twenty-six patients with a median age of 55 years were enrolled, with fourteen evaluable for the primary outcome, although all patients were included for secondary endpoints.
  • Two patients had Grade 4 treatment-related serious adverse events that required hospitalization.
  • There were no treatment-related deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Central Nervous System Neoplasms / drug therapy. Glioblastoma / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Aug 12;356(9229):566-7 [10950238.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):23-6 [12014864.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6621-8 [14528287.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2044-6 [15470485.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):221-8 [15936253.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):299-304 [16085147.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1549-51 [16350272.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16687729.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16696148.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):420-2 [16680743.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1883-90 [16986123.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Sep;4(9):658-9 [17099621.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2339-43 [17107907.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):216-22 [18314417.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):113-8 [18438609.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • (PMID = 18661102.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS539769; NLM/ PMC3885231
  •  go-up   go-down


22. Kutsuzawa K, Tada S, Hossain S, Fukuda K, Maruyama K, Akiyama Y, Akaike T, Chowdhury EH: Disrupting actin filaments promotes efficient transfection of a leukemia cell line using cell adhesive protein-embedded carbonate apatite particles. Anal Biochem; 2009 May 1;388(1):164-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells such as leukemia and lymphoma cells are obvious and attractive targets for gene therapy.
  • Moreover, genetically modified leukemia cells expressing costimulatory molecules or cytokines are likely to have significant therapeutic roles for patients with leukemia.
  • Recently, we reported on the development of a safe, efficient nanocarrier system of carbonate apatite that can assist both intracellular delivery and release of DNA, leading to very high level of transgene expression in cancer and primary cells.
  • Moreover, transgene expression efficiency could be enhanced dramatically with the cell adhesive protein-embedded particles finally up to 150 times by selectively disrupting the actin filaments.
  • [MeSH-major] Actin Cytoskeleton / drug effects. Apatites / chemistry. Cell Adhesion Molecules / metabolism. Transfection / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454213.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apatites; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Fibronectins; 55326-60-8 / carboapatite
  •  go-up   go-down


23. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML: Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood; 2009 Feb 26;113(9):2014-21
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone).
  • Treatment of prednisolone-resistant Jurkat and Molt4 cells with 2-deoxy-D-glucose (2-DG), lonidamine (LND), or 3-bromopyruvate (3-BrPA) increased the in vitro sensitivity to glucocorticoids, while treatment of the prednisolone-sensitive cell lines Tom-1 and RS4; 11 did not influence drug cytotoxicity.
  • This sensitizing effect of the glycolysis inhibitors in glucocorticoid-resistant ALL cells was not found for other classes of antileukemic drugs (ie, vincristine and daunorubicin).
  • Moreover, down-regulation of the expression of GAPDH by RNA interference also sensitized to prednisolone, comparable with treatment with glycolytic inhibitors.
  • Importantly, the ability of 2-DG to reverse glucocorticoid resistance was not limited to cell lines, but was also observed in isolated primary ALL cells from patients.
  • [MeSH-major] Drug Resistance, Neoplasm. Glycolysis / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisolone / therapeutic use
  • [MeSH-minor] Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Daunorubicin / administration & dosage. Deoxyglucose / administration & dosage. Deoxyglucose / pharmacokinetics. Drug Screening Assays, Antitumor. Drug Synergism. Gene Expression Profiling. Gene Expression Regulation, Leukemic / drug effects. Glucocorticoids / administration & dosage. Glucose / metabolism. Humans. Jurkat Cells. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1994 Dec;70(6):1047-52 [7981053.001]
  • [Cites] Future Oncol. 2007 Dec;3(6):655-64 [18041918.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2959-65 [9108416.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):509-16 [9215615.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Diabetes. 1998 Jul;47(7):1006-13 [9648821.001]
  • [Cites] Biochem Pharmacol. 1998 Oct 1;56(7):841-9 [9774146.001]
  • [Cites] Breast Cancer Res Treat. 1998 Jun;49(3):209-17 [9776504.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20281-6 [10400647.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):613-21 [15695406.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):153-60 [15860257.001]
  • [Cites] J Pathol. 2005 Jul;206(3):291-304 [15906272.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):507-14 [16044218.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1279-81 [16154856.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7435-42 [16288290.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Life Sci. 2006 Feb 16;78(12):1392-9 [16111712.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1045-9 [16574952.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4633-46 [16892078.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4683-96 [16892082.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1731-7 [17041637.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1437-46 [17301289.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3364-70 [17409446.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):300-10 [17125916.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2101-11 [18042802.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21797-800 [10823814.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9519-25 [11120745.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5575-84 [12101249.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2276-88 [12134068.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):919-29 [12648060.001]
  • [Cites] J Neurooncol. 2003 May;63(1):81-6 [12814259.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1358-66 [17499003.001]
  • [Cites] Chemotherapy. 2007;53(4):233-56 [17595539.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33384-91 [12810720.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):31-4 [14729604.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75 [15465013.001]
  • [Cites] Clin Exp Immunol. 1977 Apr;28(1):1-18 [324671.001]
  • [Cites] J Natl Cancer Inst. 1981 Mar;66(3):497-9 [6937706.001]
  • [Cites] Anal Biochem. 1987 Mar;161(2):508-13 [3555157.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23757-63 [8089148.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):108-13 [17692803.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):267-74 [17551814.001]
  • [Cites] Cell Signal. 2008 Jan;20(1):21-30 [17716864.001]
  • [Cites] Eur J Biochem. 1996 Oct 15;241(2):403-10 [8917436.001]
  • (PMID = 18978206.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 9G2MP84A8W / Deoxyglucose; 9PHQ9Y1OLM / Prednisolone; IY9XDZ35W2 / Glucose; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC4081395
  •  go-up   go-down


24. Pepper C, Lowe H, Fegan C, Thurieau C, Thurston DE, Hartley JA, Delavault P: Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Br J Cancer; 2007 Jul 16;97(2):253-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we set out to establish whether fludarabine could enhance the DNA interstrand crosslinking capacity of SJG-136 in primary human chronic lymphocytic leukaemia (CLL) cells and thereby offer a rationale for its clinical use in combination with SJG-136.
  • SJG-136 rapidly induced DNA crosslinking in primary CLL cells which was concentration-dependent.
  • The data presented here provides a clear indication that this combination of drugs may have clinical utility as salvage therapy in drug-resistant CLL.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. DNA / drug effects. DNA / genetics. DNA Repair / drug effects. Drug Synergism. Female. Humans. Male. Middle Aged. Transcription, Genetic / drug effects. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Dec 15;108(13):4187-93 [16954499.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2 Suppl 2):S50-4 [16549115.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Blood. 2002 Jul 1;100(1):224-9 [12070031.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2454-60 [12446453.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Dec;6(4):335-49; discussion 449-50 [12823776.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6693-9 [15374986.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6700-6 [15374987.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6750-5 [15374993.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2239-45 [15512812.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Blood. 1987 Mar;69(3):929-36 [3814821.001]
  • [Cites] Radiat Res. 1990 Apr;122(1):86-94 [2320728.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 7;44(1):59-64 [1632839.001]
  • [Cites] Mol Pharmacol. 1995 May;47(5):1072-9 [7746274.001]
  • [Cites] Acta Haematol. 1997;98(1):8-13 [9210907.001]
  • [Cites] Mol Pharmacol. 1997 Nov;52(5):798-806 [9351970.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):507-12 [10100700.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Nucleic Acids Res. 2005;33(10):3283-91 [15944449.001]
  • [Cites] J Med Chem. 2001 Mar 1;44(5):737-48 [11262084.001]
  • (PMID = 17579621.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione); 0 / Antineoplastic Agents; 0 / Benzodiazepinones; 0 / Cross-Linking Reagents; 0 / DNA-Binding Proteins; 0 / Pyrroles; 9007-49-2 / DNA; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2360304
  •  go-up   go-down


25. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood; 2010 Aug 12;116(6):886-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with chronic lymphocytic leukemia (CLL) with primary resistance to fludarabine-based therapy or with progressive disease were eligible for oral forodesine (200 mg/d) for up to 24 weeks.
  • Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5).
  • [MeSH-major] Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacokinetics. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Purine Nucleosides / administration & dosage. Purine Nucleosides / pharmacokinetics. Pyrimidinones / administration & dosage. Pyrimidinones / pharmacokinetics. Vidarabine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Aged. Antineoplastic Agents / administration & dosage. Apoptosis / drug effects. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Lymphocyte Count. Lymphocytes / cytology. Lymphocytes / drug effects. Male. Middle Aged. Phosphoric Monoester Hydrolases / metabolism. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. Purine-Nucleoside Phosphorylase / metabolism. Severity of Illness Index

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):195-200 [11275369.001]
  • [Cites] Blood. 2010 Aug 19;116(7):1083-91 [20442367.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):1199-210 [11407314.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):541-8 [12689658.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Leukemia. 2004 Mar;18(3):385-93 [14737075.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):644-7 [5768862.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):103-8 [6765955.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):588-91 [6937239.001]
  • [Cites] Annu Rev Biochem. 1981;50:845-77 [6267992.001]
  • [Cites] Br J Haematol. 1981 Sep;49(1):23-8 [6974004.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:191-9 [3094325.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Biochemistry. 1998 Jun 16;37(24):8615-21 [9628722.001]
  • [Cites] Immunopharmacology. 1998 Jul;40(1):1-9 [9776473.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1268-78 [18279955.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1563-75 [19541822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8 [11287638.001]
  • (PMID = 20427701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00289549
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA81534; United States / PHS HHS / / P30-16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.1.3.2 / Phosphoric Monoester Hydrolases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2924226
  •  go-up   go-down


26. Hayden RE, Pratt G, Drayson MT, Bunce CM: Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica; 2010 Nov;95(11):1889-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.
  • The proliferative and survival signals in these proliferation centers include interactions with T lymphocytes expressing CD40 ligand.
  • DESIGN AND METHODS: Primary chronic lymphocytic leukemia and peripheral blood mononuclear cells were exposed to drug combinations for 72 hours on control and CD40 ligand-expressing fibroblast monolayers.
  • The effect of CD40 ligand and drug treatments on mitochondrial superoxide levels were assessed.
  • CONCLUSIONS: Our data indicate the potential of bezafibrate, medroxyprogesterone acetate and lycorine as novel therapy in chronic lymphocytic leukemia and have important implications for the reported potential of c-abl kinase inhibitors in this disease.
  • [MeSH-major] Amaryllidaceae Alkaloids / pharmacology. Antigens, CD40 / metabolism. Bezafibrate / pharmacology. CD40 Ligand / metabolism. Drug Resistance, Neoplasm / drug effects. Enzyme Inhibitors / pharmacology. Hypolipidemic Agents / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell. Phenanthridines / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Coculture Techniques. Female. Fibroblasts / metabolism. Humans. L Cells (Cell Line). Male. Mice. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 15;112(13):5141-9 [18796631.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):698-706 [19062342.001]
  • [Cites] Leukemia. 2009 Feb;23(2):292-304 [18923439.001]
  • [Cites] Leuk Lymphoma. 2009 Feb;50(2):171-8 [19197731.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):3121-30 [19293181.001]
  • [Cites] Planta Med. 2009 Apr;75(5):501-7 [19235683.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4403-13 [19008458.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4769-75 [19487289.001]
  • [Cites] Phytochemistry. 2009 May;70(7):913-9 [19464034.001]
  • [Cites] Blood Rev. 2009 Sep;23(5):217-24 [19643519.001]
  • [Cites] Org Lett. 2009 Aug 6;11(15):3506-9 [19591492.001]
  • [Cites] PLoS One. 2009;4(12):e8147 [19997560.001]
  • [Cites] Acta Biochim Pol. 2010;57(1):75-82 [20066175.001]
  • [Cites] Mini Rev Med Chem. 2010 Jan;10(1):41-50 [20105122.001]
  • [Cites] Br J Haematol. 2010 Apr;149(1):65-9 [20067564.001]
  • [Cites] Anal Biochem. 1998 Mar 1;257(1):80-8 [9512776.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):995-1004 [10520003.001]
  • [Cites] Br J Haematol. 2004 Nov;127(4):404-15 [15521917.001]
  • [Cites] FEBS Lett. 2004 Dec 17;578(3):245-50 [15589827.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2365-72 [15621749.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Antiviral Res. 2005 Jul;67(1):18-23 [15885816.001]
  • [Cites] Immunology. 2000 Oct;101(2):201-9 [11012773.001]
  • [Cites] Leukemia. 2003 Mar;17(3):568-75 [12646946.001]
  • [Cites] Phytother Res. 2003 Dec;17(10):1220-3 [14669261.001]
  • [Cites] Br J Haematol. 2004 May;125(3):294-317 [15086411.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(2):145-52 [2431803.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):925-35 [7681471.001]
  • [Cites] Leuk Lymphoma. 1993 May;10(1-2):49-56 [8374523.001]
  • [Cites] Haematologica. 1993 Jul-Aug;78(4):213-8 [8294052.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] Am J Physiol. 1996 Jul;271(1 Pt 1):L150-8 [8760145.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1362-8 [15845901.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):911-6 [16162967.001]
  • [Cites] Nat Prod Rep. 2006 Apr;23(2):181-99 [16572227.001]
  • [Cites] Chem Biol Drug Des. 2006 May;67(5):355-63 [16784460.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 22):1-10; quiz 11-2 [17143256.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):1-10 [16600475.001]
  • [Cites] Oncol Rep. 2007 Feb;17(2):377-84 [17203177.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):300-10 [17125916.001]
  • [Cites] Biomed Pharmacother. 2007 May;61(4):229-34 [17336028.001]
  • [Cites] J Dig Dis. 2007 May;8(2):82-8 [17532820.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Dec;64(3):234-46 [17544290.001]
  • [Cites] J Virol. 2007 Dec;81(24):13392-402 [17928345.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Antiviral Res. 2008 Mar;77(3):232-6 [18243348.001]
  • [Cites] Blood. 2008 Aug 1;112(3):711-20 [18497318.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1443-52 [18550857.001]
  • [Cites] Cancer Lett. 2009 Feb 8;274(1):16-24 [18829157.001]
  • (PMID = 20634492.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Amaryllidaceae Alkaloids; 0 / Antigens, CD40; 0 / Enzyme Inhibitors; 0 / Hypolipidemic Agents; 0 / Phenanthridines; 147205-72-9 / CD40 Ligand; I9Q105R5BU / lycorine; Y9449Q51XH / Bezafibrate
  • [Other-IDs] NLM/ PMC2966911
  •  go-up   go-down


27. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V: A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood; 2007 Sep 15;110(6):1762-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro investigations with clofarabine in combination with cyclophosphamide in primary cells have demonstrated synergistic cytotoxicity and inhibition of DNA repair.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] Blood. 2006 Jul 15;108(2):473-9 [16551966.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4187-93 [16954499.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3537-43 [11071652.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3580-9 [11705880.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):859-66 [12802926.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4347-50 [12907603.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Leukemia. 2004 Feb;18(2):293-302 [14671635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):331-5 [14751500.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4205-7 [3731087.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):557-64 [2005641.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4 [1348362.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • (PMID = 17562873.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00293410
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057629; United States / NCI NIH HHS / CA / CA57629
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / H2AFX protein, human; 0 / Histones; 762RDY0Y2H / clofarabine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC1976362
  •  go-up   go-down


28. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr: Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood; 2009 Apr 30;113(18):4319-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we show that Bzb promotes matrix mineralization and calcium deposition by osteoprogenitor cells and primary mesenchymal stem cells via Wnt-independent activation of beta-catenin/TCF signaling.
  • These results provide evidence that Bzb induces OB differentiation via Wnt-independent activation of beta-catenin/TCF pathway and suggest that proteasome inhibition therapy in MM may function in part by subverting tumor-induced suppression of canonical Wnt signaling in the bone microenvironment.
  • [MeSH-major] Boronic Acids / pharmacology. Cell Differentiation / drug effects. Osteoblasts / cytology. Pyrazines / pharmacology. Signal Transduction. TCF Transcription Factors / metabolism. Wnt Proteins / metabolism. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jun 1;99(11):4138-46 [12010818.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2635-43 [17395698.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2094-8 [12424190.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1536-45 [12629517.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1771-82 [12782679.001]
  • [Cites] Immunol Rev. 2003 Aug;194:140-63 [12846813.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27939-44 [12738770.001]
  • [Cites] J Bone Miner Res. 2003 Oct;18(10):1842-53 [14584895.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2016-23 [15026338.001]
  • [Cites] Anal Biochem. 2004 Jun 1;329(1):77-84 [15136169.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):469-74 [15205949.001]
  • [Cites] Cell. 1994 Sep 9;78(5):761-71 [8087844.001]
  • [Cites] Annu Rev Biochem. 1996;65:801-47 [8811196.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):295-312 [9027589.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):633-44 [9556063.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2819-25 [9652750.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:59-88 [9891778.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):345-57 [10368775.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21464-70 [10409711.001]
  • [Cites] Dev Cell. 2005 May;8(5):727-38 [15866163.001]
  • [Cites] Dev Cell. 2005 May;8(5):739-50 [15866164.001]
  • [Cites] Dev Cell. 2005 May;8(5):751-64 [15866165.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21162-8 [15802266.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1786-93 [15886323.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):71-3 [16173965.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1283-96 [16522681.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):986-91 [16293576.001]
  • [Cites] J Cell Sci. 2006 Jun 15;119(Pt 12):2613-20 [16763196.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):233-8 [16923110.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1728-31 [16646053.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14 [17026821.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):688-92 [17107351.001]
  • [Cites] Bone. 2008 Apr;42(4):669-80 [18294945.001]
  • [Cites] Endocrinology. 2008 Apr;149(4):1793-801 [18174290.001]
  • [Cites] Eur J Haematol. 2008 Jun;80(6):490-4 [18331598.001]
  • [Cites] Blood. 2008 Jul 1;112(1):196-207 [18305214.001]
  • [Cites] Blood. 2008 Jul 15;112(2):374-82 [18344425.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2247-56 [18769451.001]
  • [Cites] Blood. 2009 Jan 15;113(3):517-25 [18687985.001]
  • [Cites] Blood. 2007 Jul 1;110(1):334-8 [17371942.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1098-104 [17494860.001]
  • [Cites] Br J Haematol. 2007 Nov;139(3):434-8 [17910634.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):491-504 [18219387.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2833-42 [18094333.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):643-50 [18242177.001]
  • [Cites] Bone. 2000 Dec;27(6):785-94 [11113389.001]
  • [Cites] Nat Med. 2007 Feb;13(2):156-63 [17237793.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2106-11 [17068150.001]
  • [Cites] Blood. 2007 May 15;109(10):4470-7 [17255354.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4646-7; author reply 4647 [12066787.001]
  • (PMID = 19196662.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Cadherins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / RNA, Messenger; 0 / TCF Transcription Factors; 0 / Wnt Proteins; 0 / beta Catenin; 69G8BD63PP / Bortezomib; EC 1.13.12.- / Luciferases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2676089
  •  go-up   go-down






Advertisement